Einhorn L H, Nagy C, Furnas B, Williams S D
J Clin Pharmacol. 1981 Aug-Sep;21(S1):64S-69S. doi: 10.1002/j.1552-4604.1981.tb02576.x.
Eighty evaluable patients receiving chemotherapy were entered on a random prospective double-blind study to evaluate the effectiveness of nabilone, a synthetic cannabinoid, compared to prochlorperazine. Most of these patients received cisplatin, a drug that universally produces severe nausea and vomiting, as part of a combination chemotherapy regimen. The patients served as their own controls, receiving either nabilone or prochlorperazine during two consecutive treatment courses with the identical chemotherapy. Side effects consisting of hypotension and lethargy were more pronounced with nabilone. Toxicity, in general, did not preclude antiemetic treatment and in no way interfered with chemotherapy. Sixty patients (75 per cent) reported nabilone to be more effective than prochlorperazine for relief of nausea and vomiting. Of these 60 patients, 46 required further chemotherapy and continued taking nabilone as the antiemetic of choice.
80名接受化疗的可评估患者进入一项随机前瞻性双盲研究,以评估合成大麻素纳必隆与丙氯拉嗪相比的有效性。这些患者大多数接受顺铂治疗,顺铂是一种普遍会引起严重恶心和呕吐的药物,作为联合化疗方案的一部分。患者自身作为对照,在两个连续的相同化疗疗程中分别接受纳必隆或丙氯拉嗪治疗。纳必隆引起的包括低血压和嗜睡在内的副作用更为明显。总体而言,毒性并不妨碍止吐治疗,也丝毫没有干扰化疗。60名患者(75%)报告纳必隆在缓解恶心和呕吐方面比丙氯拉嗪更有效。在这60名患者中,46名需要进一步化疗,并继续将纳必隆作为首选止吐药服用。